ORX Stock Overview
A specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Orexo AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 19.26 |
| 52 Week High | SEK 24.00 |
| 52 Week Low | SEK 9.18 |
| Beta | 0.58 |
| 1 Month Change | 101.68% |
| 3 Month Change | 36.21% |
| 1 Year Change | 18.45% |
| 3 Year Change | -44.04% |
| 5 Year Change | -69.43% |
| Change since IPO | -78.60% |
Recent News & Updates
A Piece Of The Puzzle Missing From Orexo AB (publ)'s (STO:ORX) 105% Share Price Climb
Dec 20
Orexo AB (publ) (STO:ORX) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Nov 05Recent updates
A Piece Of The Puzzle Missing From Orexo AB (publ)'s (STO:ORX) 105% Share Price Climb
Dec 20Orexo AB (publ) (STO:ORX) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Nov 05Orexo AB (publ) (STO:ORX) Might Not Be As Mispriced As It Looks After Plunging 28%
Aug 02Orexo AB (publ) (STO:ORX) Just Reported Earnings, And Analysts Cut Their Target Price
Jul 20Orexo AB (publ) (STO:ORX) Soars 28% But It's A Story Of Risk Vs Reward
May 29Orexo AB (publ)'s (STO:ORX) Business And Shares Still Trailing The Industry
Apr 03We Think Orexo (STO:ORX) Has A Fair Chunk Of Debt
Dec 09Orexo AB (publ)'s (STO:ORX) Intrinsic Value Is Potentially 24% Below Its Share Price
Jun 14Is Orexo (STO:ORX) A Risky Investment?
Apr 27Orexo AB (publ)'s (STO:ORX) Intrinsic Value Is Potentially 92% Above Its Share Price
Oct 19Would Orexo (STO:ORX) Be Better Off With Less Debt?
Sep 09Are Investors Undervaluing Orexo AB (publ) (STO:ORX) By 47%?
May 26Is Orexo (STO:ORX) Using Too Much Debt?
Apr 16Shareholder Returns
| ORX | SE Pharmaceuticals | SE Market | |
|---|---|---|---|
| 7D | 12.4% | 0.4% | -2.7% |
| 1Y | 18.5% | -2.4% | 4.6% |
Return vs Industry: ORX exceeded the Swedish Pharmaceuticals industry which returned -2.4% over the past year.
Return vs Market: ORX exceeded the Swedish Market which returned 4.6% over the past year.
Price Volatility
| ORX volatility | |
|---|---|
| ORX Average Weekly Movement | 11.5% |
| Pharmaceuticals Industry Average Movement | 9.0% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in SE Market | 11.4% |
| 10% least volatile stocks in SE Market | 3.2% |
Stable Share Price: ORX's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: ORX's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 113 | Nikolaj Sorensen | www.orexo.com |
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 for emergency treatment of allergic reactions; and OX-MPI for the treatment of endometriosis.
Orexo AB (publ) Fundamentals Summary
| ORX fundamental statistics | |
|---|---|
| Market cap | SEK 664.57m |
| Earnings (TTM) | -SEK 105.30m |
| Revenue (TTM) | SEK 595.70m |
1.1x
P/S Ratio-6.3x
P/E RatioIs ORX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ORX income statement (TTM) | |
|---|---|
| Revenue | SEK 595.70m |
| Cost of Revenue | SEK 69.80m |
| Gross Profit | SEK 525.90m |
| Other Expenses | SEK 631.20m |
| Earnings | -SEK 105.30m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 06, 2025
| Earnings per share (EPS) | -3.05 |
| Gross Margin | 88.28% |
| Net Profit Margin | -17.68% |
| Debt/Equity Ratio | -1,688.6% |
How did ORX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 01:26 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Orexo AB (publ) is covered by 12 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sten Gustafsson | ABG Sundal Collier |
| Klas Palin | Carnegie Commissioned Research |
| Kristofer Liljeberg-Svensson | Carnegie Investment Bank AB |